In the BRUIN study, which included CLL, MCL, DLBCL, WM, FL, marginal zone lymphoma (MZL), and primary central nervous system lymphoma (PCNSL), patients treated with pirtobrutinib, formerly LOXO-305, and patients with heavily relapsed and refractory CLL, including those previously treated with BTK inhibitors, were shown to have an overall response rate of 74% [47]. Here, BTK is linked to diffuse large B-cell lymphoma.